RegeneRx
Contact Us


Overview

Our Mission

To develop and commercialize novel pharmaceutical products that prevent or repair tissue and organ damage caused by disease, trauma, or other pathology. More>>

Stock Quote
RGN (Common Stock)
ExchangeNYSE AMEX (US Dollar)
Price$0.26
Change (%) Stock is Up 0.01 (4.00%)
Volume25,919
Data as of 09/03/10 3:59 p.m. ET
Minimum 20 minute delay
Refresh quote
Featured Report
Download Documentation Fact Sheet July 2009
Recent NewsMore >>
DateTitle 
09/02/10RegeneRx Appoints R. Don Elsey to Board of DirectorsPrinter Friendly Version
08/02/10British Researchers Report that TB4 is Essential to Heart DevelopmentPrinter Friendly Version
07/19/10Researchers Report in Neuroscience that TB4 Improves Neurological Function after StrokePrinter Friendly Version
07/08/10RegeneRx Awarded Australian Patent for New TB4 ApplicationsPrinter Friendly Version
Contact Information
Primary IR Contact
C. Neil Lyons
Chief Financial Officer
RegeneRx Biopharmaceuticals, Inc.
15245 Shady Grove Road
Suite 470
Rockville, MD 20850
Phone: 301-208-9191
Fax: 301-208-9194
E-mail: info@regenerx.com

Transfer Agent
American Stock Transfer
6201 15th Avenue
Brooklyn, NY 11219
Phone: 800-937-5449


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

     
home|Contact Us|Resources|Site Map|
Search